Well - 2 questions for the price of 1 in this post. These questions occurred to me as I was doing some catch-up monitoring on SELB and HZNP (makers of KRYSTEXXA) and saw the upcoming SEL-212 readout in our catalyst database (you should check it out if you're looking for companies with upcoming catalyst events).
We haven't followed SELB closely this year. Would enjoy reader comments re: why the runup? Is it a runup into the COMPARE readout?
But isn't COMPARE flawed in its design? The SELB COMPARE trial is testing SEL-212 vs. KRYSTEXXA per its current label (methotrexate (MTX) only in run-in period but not after first administration), whereas HZNP MIRROR compares KRYSTEXXA per its current label to KRYSTEXXA given biweekly and MTX administered weekly throughout KRYSTEXXA administration period. There is at least one investigator study (https://ard.bmj.com/content/78/Suppl_2/1289.2) showing the improved results with the latter. Thus, COMPARE appears to be comparing to what is likely the old standard of care. It will be interesting to see how the market reacts to the likely "positive" COMPARE results. It seems that the best we will be able to do is to cross-trial compare to COMPARE SEL-212 to MIRROR KRYSTEXXA + weekly MTX after that reads out. You can find links to prior SEL-212 readouts and to clinicaltrials.gov entries for both MIRROR and COMPARE in our drug database entries for these drug/candidate.
*Keep in mind that our Amp forums are intended to be a safe zones with no a**holes. So feel free to respond. If we see rude or unproductive comments, we will delete them and put the author in a penalty, with ejection from site for repeat offenders.